-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: keymaster@town.hall.org Originator-Key-Asymmetric: MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5RtObb1cJ7VkACDq pKb9/DClgTKIm08lCfoilvi9Wl4SODbR1+1waHhiGmeZO8OdgLUCAwEAAQ== MIC-Info: RSA-MD5,RSA, B1RDJPxcyKvIw+np9k7EN8aFr3iOzTa1DKEN6TCBrcVTv41cHJN8WhyuH+P3puXT AHiiL1MxAPjqxUI0MrBEuQ== 0000898430-95-001336.txt : 19950731 0000898430-95-001336.hdr.sgml : 19950731 ACCESSION NUMBER: 0000898430-95-001336 CONFORMED SUBMISSION TYPE: 10-C PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19950719 FILED AS OF DATE: 19950728 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIS INTERNATIONAL INC CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-C SEC ACT: 1934 Act SEC FILE NUMBER: 000-08092 FILM NUMBER: 95556971 BUSINESS ADDRESS: STREET 1: 6040 N CUTTER CIRCLE STE 317 CITY: PORTLAND STATE: OR ZIP: 97217 BUSINESS PHONE: 5032833911 MAIL ADDRESS: STREET 1: 6040 N CUTTER CIRCLE STE 317 CITY: PORTLAND STATE: OR ZIP: 97217 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 10-C 1 FORM 10-C DATED 07/19/95 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-C REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ INTERDEALER QUOTATION SYSTEM FILED PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 13A-17 OR 15D-17 THEREUNDER OXIS INTERNATIONAL, INC. - -------------------------------------------------------------------------------- (EXACT NAME OF ISSUER AS SPECIFIED IN CHARTER) 6040 N. CUTTER CIRCLE, SUITE 317, PORTLAND, OR. 97217-3935 - -------------------------------------------------------------------------------- (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) Issuer's telephone number, including area code (503) 283-3911 -------------- I. CHANGE IN NUMBER OF SHARES OUTSTANDING Indicate any change (increase or decrease) of five percent or more in the number of shares outstanding: 1. Title of security Common Stock --------------------------------------------------------- 2. Number of shares outstanding before the change 10,683,687 --------------------------- 3. Number of shares outstanding after the change 12,124,423 --------------------------- 4. Effective date of change July 19, 1995 ------------------------------------------------- 5. Method of change: Specify method (such as merger, acquisition, exchange, distribution, stock split, reverse split, acquisition of stock for treasury, etc.) Merger - ------------------------------------------------------------------------------ Give brief description of transaction: On July 19, 1995, Therox ------------------------ Pharmaceuticals, Inc. ("Therox") was merged with and into OXIS Acquisition - -------------------------------------------------------------------------- Corporation ("OXISub"), a wholly-owned subsidiary of Issuer with OXISub as the - ------------------------------------------------------------------------------ surviving corporation. An aggregate of 1,440,736 shares of Issuer's Common - --------------------------------------------------------------------------- Stock was issued in exchange for all of the outstanding shares of Therox stock. - ------------------------------------------------------------------------------- Date: July 26, 1995 /s/ Ray R. Rogers ---------------------------- Ray R. Rogers Chairman of the Board, OXIS International, Inc. -----END PRIVACY-ENHANCED MESSAGE-----